Почетна › Акутна миелоидна леукемија › Alabama
Клинички испитувања за Акутна миелоидна леукемија во Alabama
21 студии за Акутна миелоидна леукемија бараат учесници на локации во Alabama.
Градови во Alabama
Официјален текст на студијата (англиски)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
Се регрутираФаза 1
До возраст 21 · Сите полови · Ажурирано 5.10.2026 · NCT07012044Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Се регрутираФаза 2
Возраст од 18 до 59 · Сите полови · Ажурирано 28.9.2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06852222Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Се регрутираФаза 2
Возраст од 18 до 59 · Сите полови · Ажурирано 22.9.2026 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06317649A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
Се регрутираФаза 3
6 Months – 21 Years · Сите полови · Ажурирано 17.9.2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- University of Alabama - Birmingham, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT06824168Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
Се регрутираФаза 3
Возраст од 1 до 25 · Сите полови · Ажурирано 4.9.2026 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 3.9.2026 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
Се регрутираФаза 1/2
До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Alabama Birmingham, Birmingham
Се регрутираФаза 2/3
Возраст од 18 до 80 · Сите полови · Ажурирано 5.8.2026 · NCT06788756A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Alabama at Birmingham, Birmingham
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Се регрутира
Возраст 60 и постари · Сите полови · Ажурирано 6.7.2026 · NCT06697600A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
Се регрутираФаза 2
Возраст од 18 до 66 · Сите полови · Ажурирано 17.3.2026 · NCT06859424Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 1
Возраст од 18 до 75 · Сите полови · Ажурирано 4.3.2026 · NCT07044544CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- University of Alabama O'Neal Cancer Center, Birmingham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 16.1.2026 · NCT05143996HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
Се регрутираНабљудувачка студија
Возраст од 12 до 80 · Сите полови · Ажурирано 28.8.2025 · NCT07145411Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- The Kirklin Clinic of UAB Hospital, Birmingham
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 26.8.2025 · NCT03850574Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- University of Alabama - Birmingham, Birmingham
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 120 · Сите полови · Ажурирано 25.7.2025 · NCT05237258Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 15.11.2024 · NCT06034275Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.